Literature DB >> 17393952

The prevention of pain from sickle cell disease by trandolapril.

R Michael Williams1, David W Moskowitz.   

Abstract

A 48-year-old African-American woman with both sickle cell anemia and chronic pain was treated with a hydrophobic angiotensin I-converting enzyme (ACE) inhibitor. This resulted in the complete resolution of her pain. When the ACE inhibitor was deliberately stopped, her pain recurred, only to cease again after the ACE inhibitor was deliberately resumed. The activation of ACE may be an early step in the arterial vaso-occlusion typical of sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17393952      PMCID: PMC2569632     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  10 in total

Review 1.  Coagulopathies and arterial stroke.

Authors:  Mark L Moster
Journal:  J Neuroophthalmol       Date:  2003-03       Impact factor: 3.042

2.  Risk of venous thromboembolism associated with the insertion/deletion polymorphism in the angiotensin-converting enzyme gene.

Authors:  A J González Ordóñez; J M Fernández Carreira; J M Medina Rodríguez; L Martín Sánchez; R Alvarez Díaz; M V Alvarez Martinez; E Coto Garcia
Journal:  Blood Coagul Fibrinolysis       Date:  2000-07       Impact factor: 1.276

3.  Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.

Authors:  Mark T Gladwin; Gregory J Kato
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

Review 4.  Is "somatic" angiotensin I-converting enzyme a mechanosensor?

Authors:  David W Moskowitz
Journal:  Diabetes Technol Ther       Date:  2002       Impact factor: 6.118

5.  Is angiotensin I-converting enzyme a "master" disease gene?

Authors:  David W Moskowitz
Journal:  Diabetes Technol Ther       Date:  2002       Impact factor: 6.118

6.  Relation of three genetic traits to venous thrombosis in an African-American population.

Authors:  A Dilley; H Austin; W C Hooper; C Lally; M J Ribeiro; N K Wenger; V Silva; P Rawlins; B Evatt
Journal:  Am J Epidemiol       Date:  1998-01-01       Impact factor: 4.897

Review 7.  Hypertension, thermotolerance, and the "African gene": an hypothesis.

Authors:  D W Moskowitz
Journal:  Clin Exp Hypertens       Date:  1996-01       Impact factor: 1.749

Review 8.  The central role of angiotensin I-converting enzyme in vertebrate pathophysiology.

Authors:  David W Moskowitz; Frank E Johnson
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

9.  From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example.

Authors:  David W Moskowitz
Journal:  Diabetes Technol Ther       Date:  2002       Impact factor: 6.118

Review 10.  Angiotensin II-mediated renal injury.

Authors:  R C Harris; M Martinez-Maldonado
Journal:  Miner Electrolyte Metab       Date:  1995
  10 in total
  3 in total

Review 1.  A review of the literature on the multiple dimensions of chronic pain in adults with sickle cell disease.

Authors:  Lou Ella V Taylor; Nancy A Stotts; Janice Humphreys; Marsha J Treadwell; Christine Miaskowski
Journal:  J Pain Symptom Manage       Date:  2010-07-24       Impact factor: 3.612

2.  The relationship of oxygen transport and cardiac index for the prevention of sickle cell crises.

Authors:  Kevin Farrell; Leon Dent; Minh Ly Nguyen; Maciej Buchowski; Ananta Bhatt; Maria del Pilar Aguinaga
Journal:  J Natl Med Assoc       Date:  2010-11       Impact factor: 1.798

3.  Routine paediatric sickle cell disease (SCD) outpatient care in a rural Kenyan hospital: utilization and costs.

Authors:  Djesika D Amendah; George Mukamah; Albert Komba; Carolyne Ndila; Thomas N Williams
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.